Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.

Cell Death Differ 2020 Sep 28. Epub 2020 Sep 28.

Biotherapeutics Translational Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), 125 Gwahak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea.

Gallbladder carcinoma (GBC) exhibits poor prognosis due to local recurrence, metastasis, and resistance to targeted therapies. Using clinicopathological analyses of GBC patients along with molecular in vitro and tumor in vivo analysis of GBC cells, we showed that reduction of Dsg2 expression was highly associated with higher T stage, more perineural, and lymphatic invasion. Dsg2-depleted GBC cells exhibited significantly enhanced proliferation, migration, and invasiveness in vitro and tumor growth and metastasis in vivo through Src-mediated signaling activation. Interestingly, Dsg2 binding inhibited Src activation, whereas its loss activated cSrc-mediated EGFR plasma membrane clearance and cytoplasmic localization, which was associated with acquired EGFR-targeted therapy resistance and decreased overall survival. Inhibition of Src activity by dasatinib enhanced therapeutic response to anti-EGFR therapy. Dsg2 status can help stratify predicted patient response to anti-EGFR therapy and Src inhibition could be a promising strategy to improve the clinical efficacy of EGFR-targeted therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41418-020-00628-4DOI Listing
September 2020

Publication Analysis

Top Keywords

egfr-targeted therapy
12
gallbladder carcinoma
8
vitro tumor
8
anti-egfr therapy
8
response anti-egfr
8
gbc cells
8
therapy src
8
therapy
5
enhanced proliferation
4
exhibited enhanced
4
cells exhibited
4
proliferation migration
4
growth metastasis
4
metastasis vivo
4
tumor growth
4
therapeutic response
4
migration invasiveness
4
invasiveness vitro
4
dsg2-depleted gbc
4
lymphatic invasion
4

Similar Publications